I-SENS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
March 20, 2024 at 04:15 am EDT
Share
i-SENS, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 1,411.33 million compared to KRW 2,730.53 million a year ago. Net income was KRW 3,709.06 million compared to KRW 16,138.02 million a year ago.
Basic earnings per share from continuing operations was KRW 135 compared to KRW 588 a year ago. Diluted earnings per share from continuing operations was KRW 134. Basic earnings per share was KRW 135 compared to KRW 588 a year ago.
i-SENS, Inc. is a Korea-based company mainly engaged in the manufacture and sale of biosensors. The Companyâs products consist of blood glucose monitoring systems, including blood glucose monitors, blood glucose meters, glucose monitors, blood glucose meter kits and blood sugar meters under the brand names of CareSens, MedTrust, BGStar, Barozen and others; electrolyte analyzers and cartridges; immunosensors, as well as other related accessories, such as connectors, lancets, blood glucose data management software and lancing devices, among others. The Company distributes its products within domestic market and to overseas markets including Japan, Europe, the United States and others.
I-SENS, INC. 
